aegerion pharmaceuticals inc
(AEGR:NASDAQ GS)

Executive Profile*

Background*

Ms. Martha J. Carter, RAC has been the Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, Inc. since February 2011. Ms. Carter served as Chief Regulatory Officer of Proteon Therapeutics Inc. She served as Senior Vice President of Regulatory Affairs and Quality Assurance of Proteon Therapeutics Inc. since 2006. Ms. Carter served as Senior Vice President of Regulatory Affairs of Trine Pharmaceuticals Inc. (formerly known as Essential Therapeutics ... Inc.) since September 2002. Prior to joining Essential, She served as Vice President, Regulatory Affairs of GelTex Pharmaceuticals Inc. from 1998 to 2002. Prior to joining GelTex, she served at Genetics Institute as Director of Regulatory Affairs from 1995 to 1998. From 1992 to 1995, Ms. Carter served as Senior Director and then Vice President of Regulatory Affairs at ImmuLogic Pharmaceutical Corporation. From 1983 to 1991, she headed the regulatory affairs function at Serono Laboratories Inc. From 1977 to 1983, Ms. Carter was employed by Fisons Corporation in clinical research and regulatory affairs. She has over 30 years of regulatory and quality assurance experience. Ms. Carter received her B.A. in Biology from Northeastern University and she attended the Massachusetts College of Pharmacy and Health Sciences where she completed the didactic portion of the Master of Science degree in Therapeutics.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
AEGR:US	$58.25 USD	-1.77

COMPETITOR COMPENSATION